Inhibition of protein kinase C/twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer

Clinical Cancer Research

Volumn 20, Issue 4, 2014, Pages 951-961

  Shiota, Masaki ^a   Yokomizo, Akira ^a   Takeuchi, Ario ^a   Imada, Kenjiro ^a   Kashiwagi, Eiji ^a   Song, Yoohyun ^a   Inokuchi, Junichi ^a   Tatsugami, Katsunori ^a   Uchiumi, Takeshi ^a   Naito, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; ENZALUTAMIDE; PROTEIN KINASE C; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST 1; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; INDOLES; MALE; NUCLEAR PROTEINS; PHENYLTHIOHYDANTOIN; PHOSPHORYLATION; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN ISOFORMS; PROTEIN KINASE C; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TWIST TRANSCRIPTION FACTOR;

EID: 84896712232     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1809     Document Type: Article

References (44)

1. Sharifi N, Gulley JL, Dahut WL. An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer 2010;17:R305-15.
2. Sadar MD. Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity. Cancer Res 2011;71:1208-13.
3. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
4. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48.
5. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97.
6. Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 2011;29:3651-8.
7. Waltering KK, Urbanucci A, Visakorpi T. Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Mol Cell Endocrinol 2012;360:38-43.
8. Shiota M, Yokomizo A, Naito S. Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target. J Mol Endocrinol 2011;47:R25-41.
9. Shiota M, Yokomizo A, Fujimoto N, Naito S. Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer. Curr Cancer Drug Targets 2011;11: 870-81.
10. Inoue T, Ogawa O. Role of signaling transduction pathways in development of castration-resistant prostate cancer. Prostate Cancer. 2011;2011:647987.
11. Cai C, Balk SP. Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer 2011;18: R175-82.
12. Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, Kidani A, et al. Twist promotes tumor cell growth through YB-1 expression. Cancer Res 2008;68:98-105.
13. Shiota M, Yokomizo A, Tada Y, Inokuchi J, Kashiwagi E, Masubuchi D, et al. Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression. Oncogene 2010;29:237-50.
14. Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, et al. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res 2012;72:527-36.
15. Shiota M, Song Y, Takeuchi A, Yokomizo A, Kashiwagi E, Kuroiwa K, et al. Antioxidant therapy alleviates oxidative stress by androgen deprivation and prevents conversion from androgen dependent to castration resistant prostate cancer. J Urol 2012;187: 707-14.
16. Zeng L, Webster SV, Newton PM. The biology of protein kinase C. Adv Exp Med Biol 2012;740:639-61.
17. Benavides F, Blando J, Perez CJ, Garg R, Conti CJ, DiGiovanni J, et al. Transgenic overexpression of PKCe in the mouse prostate induces preneoplastic lesions. Cell Cycle 2011;10:268-77.
18. Hafeez BB, Zhong W, Weichert J, Dreckschmidt NE, Jamal MS, Verma AK. Genetic ablation of PKC e inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinoma. Cancer Res 2011;71:2318-27.
19. Koren R, Ben Meir D, Langzam L, Dekel Y, Konichezky M, Baniel J, et al. Expression of protein kinase C isoenzymes in benign hyperplasia and carcinoma of prostate. Oncol Rep 2004;11:321-6.
20. Kim J, Choi YL, Vallentin A, Hunrichs BS, Hellerstein MK, Peehl DM, et al. Centrosomal PKCbII and pericentrin are critical for human prostate cancer growth and angiogenesis. Cancer Res 2008;68: 6831-9.
21. Metzger E, Imhof A, Patel D, Kahl P, Hoffmeyer K, Friedrichs N, et al. Phosphorylation of histone H3T6 by PKCb(I) controls demethylation at histone H3K4. Nature 2010;464:792-6.
22. Ishiguro H, Akimoto K, Nagashima Y, Kojima Y, Sasaki T, Ishiguro-Imagawa Y, et al. aPKCl/i promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6. Proc Natl Acad Sci U S A 2009;106:16369-74.
23. Yao S, Bee A, Brewer D, Dodson A, Beesley C, Ke Y, et al. PRKC-z expression promotes the aggressive phenotype of human prostate cancer cells and is a novel target for therapeutic intervention. Genes Cancer 2010;1:444-64.
24. Inoue T, Yoshida T, Shimizu Y, Kobayashi T, Yamasaki T, Toda Y, et al. Requirement of androgen-dependent activation of protein kinase Cz for androgen-dependent cell proliferation in LNCaP cells and its roles in transition to androgen-independent cells. Mol Endocrinol 2006;20: 3053-69.
25. Shiota M, Takeuchi A, Song Y, Yokomizo A, Kashiwagi E, Uchiumi T, et al. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression. Endocr Relat Cancer 2011;18:505-17.
26. Shiota M, Takeuchi A, Yokomizo A, Kashiwagi E, Tatsugami K, Naito S. Methyltransferase inhibitor adenosine dialdehyde suppresses androgen receptor expression and prostate cancer growth. J Urol 2012; 188:300-6.
27. Lin TH, Lee SO, Niu Y, Xu D, Liang L, Li L, et al. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis. J Biol Chem 2013;288:19359-69.
28. Lin TH, Izumi K, Lee SO, Lin WJ, Yeh S, Chang C. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis 2013;4:e764
29. Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001;61: 2892-8.
30. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994;57:406-12.
31. Li Y, Hwang TH, Oseth LA, Hauge A, Vessella RL, Schmechel SC, et al. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene 2012;31:4759-67.
32. Shiota M, Yokomizo A, Naito S. Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer. Endocr Relat Cancer 2012; 19:R243-53.
33. Sabbah M, Emami S, Redeuilh G, Julien S, Prevost G, Zimber A, et al. Molecular signature and therapeutic perspective of the epithelial-tomesenchymal transitions in epithelial cancers. Drug Resist Updat 2008;11:123-51.
34. Meyer T, Regenass U, Fabbro D, Alteri E, Rosel J, Muller M, et al. A derivative of staurosporine (CGP 41251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo antitumor activity. Int J Cancer 1989;43:851-856.
35. Millward MJ, House C, Bowtell D, Webster L, Olver IN, Gore M, et al. The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study. Br J Cancer 2006;95:829-34.
36. Song HF, Tang ZM, Yuan SJ, Zhu BZ. Application of secondary structure prediction in antisense drug design targeting protein kinase C-a mRNA and QSAR analysis. Acta Pharmacol Sin 2000; 21:80-6.
37. Song HF, Tang ZM, Yuan SJ, Zhu BZ, Liu XW. Antisense candidates against protein kinase C-adesigned based on phylogenesis and simulant structure of mRNA. Acta Pharmacol Sin 2003;24: 269-76.
38. Rao S, Watkins D, Cunningham D, Dunlop D, Johnson P, Selby P, et al. Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C a, in patients with previously treated low-grade non-Hodgkin's lymphoma. Ann Oncol 2004;15:1413-8.
39. Mani S, Rudin CM, Kunkel K, Holmlund JT, Geary RS, Kindler HL, et al. Phase I clinical and pharmacokinetic study of protein kinase C-a antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin Cancer Res 2002;8:1042-8.
40. Chen YB, LaCasce AS. Enzastaurin. Expert Opin Investig Drugs 2008;17:939-44.
41. Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, et al. Phase II study of enzastaurin, a protein kinase C b inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007;25:1741-6.
42. Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010;28:1168-74.
43. Rademaker-Lakhai JM, Beerepoot LV, Mehra N, Radema SA, van Maanen R, Vermaat JS, et al. Phase I pharmacokinetic and pharmacodynamics study of the oral protein kinaseCb-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res 2007;13:4474-81.
44. Dreicer R, Garcia J, Hussain M, Rini B, Vogelzang N, Srinivas S, et al. Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease. Invest New Drugs 2011;29;1441-8. Technology Technology